We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $20.9M
1-Year Est. Return 195.52%
This Fund
S&P 500
This Quarter Est. Return
+44.85%
1 Year Est. Return
+195.52%
3 Year Est. Return
+318.83%
5 Year Est. Return
+369%
10 Year Est. Return
+2,361.28%
AUM
$19.3M
AUM Growth
+$1.72M
Cap. Flow
+$309
Cap. Flow %
0%
Top 10 Hldgs %
48.51%
Holding
42
New
15
Increased
6
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
CUE icon
Cue Biopharma
CUE
+$1.35M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$601K
3
HUMA icon
Humacyte
HUMA
+$590K
4
QURE icon
uniQure
QURE
+$567K
5
JANX icon
Janux Therapeutics
JANX
+$447K

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$1.14M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$912K
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$909K
4
INSM icon
Insmed
INSM
+$900K
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$769K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
1
Milestone Pharmaceuticals
MIST
$149M
$1.53M 7.89%
755,000
+96,447
+15% +$208K
PRAX icon
2
Praxis Precision Medicines
PRAX
$9.82B
$1.31M 6.79%
4,450
-1,250
-22% -$233K
MLTX icon
3
MoonLake Immunotherapeutics
MLTX
$1.28B
$890K 4.6%
67,500
– –
FENC icon
4
Fennec Pharmaceuticals
FENC
$434M
$866K 4.48%
112,434
-10,566
-9% -$86.7K
JSPR icon
5
Jasper Therapeutics
JSPR
$23.6M
$851K 4.4%
465,000
+66,442
+17% +$133K
BNTC icon
6
Benitec Biopharma
BNTC
$436M
$835K 4.32%
62,000
– –
RPRX icon
7
Royalty Pharma
RPRX
$28.5B
$827K 4.28%
21,400
– –
GERN icon
8
Geron
GERN
$1.01B
$763K 3.95%
578,000
+78,000
+16% +$97.9K
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.84B
$756K 3.91%
36,000
-19,000
-35% -$331K
ARDX icon
10
Ardelyx
ARDX
$976M
$750K 3.88%
128,650
-34,100
-21% -$190K
CUE icon
11
Cue Biopharma
CUE
$199M
$673K 3.48%
+73,428
New +$1.35M
IRON icon
12
Disc Medicine
IRON
$3.04B
$643K 3.33%
8,100
-2,500
-24% -$211K
SRPT icon
13
Sarepta Therapeutics
SRPT
$2.38B
$613K 3.17%
+28,500
New +$601K
BHVN icon
14
Biohaven
BHVN
$2.37B
$584K 3.02%
51,700
+29,000
+128% +$359K
HUMA icon
15
Humacyte
HUMA
$168M
$480K 2.49%
500,000
+416,500
+499% +$590K
KURA icon
16
Kura Oncology
KURA
$1.18B
$478K 2.47%
46,000
– –
MCRB icon
17
Seres Therapeutics
MCRB
$57.5M
$470K 2.43%
31,570
+4,432
+16% +$77.3K
CMPS
18
Compass Pathways
CMPS
$1.84B
$400K 2.07%
58,000
– –
DAWN
19
DELISTED
Day One Biopharmaceuticals
DAWN
$391K 2.03%
42,000
– –
RGNX icon
20
Regenxbio
RGNX
$590M
$383K 1.98%
26,600
-31,150
-54% -$388K
BBIO icon
21
BridgeBio Pharma
BBIO
$14.6B
$382K 1.98%
5,000
-8,300
-62% -$545K
MLYS icon
22
Mineralys Therapeutics
MLYS
$2.49B
$381K 1.97%
10,500
-28,500
-73% -$1.14M
VTYX
23
DELISTED
Ventyx Biosciences
VTYX
$375K 1.94%
+41,500
New +$310K
LNTH icon
24
Lantheus
LNTH
$6.59B
$366K 1.89%
+5,500
New +$320K
DYN icon
25
Dyne Therapeutics
DYN
$4.53B
$352K 1.82%
+18,000
New +$341K
1
2

Similar funds

SCM
Stadium Capital Management New Canaan, Connecticut $21M AUM 6.45% 1-Year Est. Return
MPW
MGO Private Wealth Irvine, California $20.7M AUM 18.57% 1-Year Est. Return
FS
Financially Speaking Greenwood Village, Colorado $20.6M AUM 16.79% 1-Year Est. Return
VAM
Vazirani Asset Management New York $20.3M AUM 79.33% 1-Year Est. Return
SPC
Stone Point Capital Greenwich, Connecticut $21.7M AUM 48.55% 1-Year Est. Return
SCM
Semanteon Capital Management Newton, Massachusetts $22.2M AUM 53.69% 1-Year Est. Return
HIIL
HS Investments III Ltd St. Peter Port $22.3M AUM
PMAM
Penn Mutual Asset Management Conshohocken, Pennsylvania $19.5M AUM 3.07% 1-Year Est. Return

Lion Point Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Lion Point Capital held 42 positions worth $19.3M, up 9.8% from $17.6M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Lion Point Capital's Q4 2025 filing shows 15 new, 6 increased, 10 reduced and 3 closed positions. Its largest new stake was Cue Biopharma: 73,428 shares worth $673K. The largest sale was Mineralys Therapeutics, an estimated $1.14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lion Point Capital's largest Q4 2025 buy was Cue Biopharma: 73,428 shares worth $673K.
  • Lion Point Capital added most to Humacyte in Q4 2025, an estimated $590K increase.
  • Lion Point Capital's biggest Q4 2025 reduction was Mineralys Therapeutics, cutting an estimated $1.14M.
  • Lion Point Capital fully exited Avadel Pharmaceuticals in Q4 2025, selling an estimated $912K.
  • Lion Point Capital's ten largest holdings make up 49% of its $19.3M portfolio in Q4 2025.
  • Lion Point Capital opened 15 new positions and closed 3 in Q4 2025.
  • Lion Point Capital's portfolio value rose 9.8% quarter-over-quarter to $19.3M.

Based on Lion Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.